Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy
Author | Basar, Oyku Yagmur |
Author | Mohammed, Sawsan |
Author | Qoronfleh, M. Walid |
Author | Acar, Ahmet |
Available date | 2024-06-24T07:07:13Z |
Publication Date | 2024-01-01 |
Publication Name | Frontiers in Cell and Developmental Biology |
Identifier | http://dx.doi.org/10.3389/fcell.2024.1369597 |
Citation | Basar OY, Mohammed S, Qoronfleh MW and Acar A (2024) Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy. Front. Cell Dev. Biol. 12:1369597. doi: 10.3389/fcell.2024.1369597 |
Abstract | Metronomic chemotherapy (MCT), characterized by the continuous administration of chemotherapeutics at a lower dose without prolonged drug-free periods, has garnered significant attention over the last 2 decades. Extensive evidence from both pre-clinical and clinical settings indicates that MCT induces distinct biological effects than the standard Maximum Tolerated Dose (MTD) chemotherapy. The low toxicity profile, reduced likelihood of inducing acquired therapeutic resistance, and low cost of MCT render it an attractive chemotherapeutic regimen option. One of the most prominent aspects of MCT is its anti-angiogenesis effects. It has been shown to stimulate the expression of anti-angiogenic molecules, thereby inhibiting angiogenesis. In addition, MCT has been shown to decrease the regulatory T-cell population and promote anti-tumor immune response through inducing dendritic cell maturation and increasing the number of cytotoxic T-cells. Combination therapies utilizing MCT along with oncolytic virotherapy, radiotherapy or other chemotherapeutic regimens have been studied extensively. This review provides an overview of the current status of MCT research and the established mechanisms of action of MCT treatment and also offers insights into potential avenues of development for MCT in the future. |
Sponsor | Funding The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AA was supported by the International Fellowship for Outstanding Researchers Program administrated by The Scientific and Technological Research Council of Türkiye (TUBITAK). Acknowledgments The authors want to thank their respective institutions for their continued support. AA would like to acknowledge Republic of Türkiye The Council of Higher Education Research Universities Support Program (Grant number: ADEP-108-2022-11202). |
Language | en |
Publisher | Frontiers Media |
Subject | cancer combination therapy metronomic chemotherapy photodynamic therapy therapeutic resistance |
Type | Article Review |
Volume Number | 12 |
ESSN | 2296-634X |
Files in this item
This item appears in the following Collection(s)
-
Medicine Research [1537 items ]